LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 11 of 535
Next
>>
>
251 to 275 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Dasatinib	0.12	uM	LJP5	2	D05	72	hr	1657	3141	5610	0.5598	0.4381
BT-20	Dasatinib	0.12	uM	LJP5	3	D05	72	hr	1657	3919	5529	0.7088	0.6407
BT-20	Dasatinib	0.37	uM	LJP6	2	I04	72	hr	1657	1539	5360	0.2871	-0.0429
BT-20	Dasatinib	0.37	uM	LJP6	3	I04	72	hr	1657	1697	5546	0.3060	0.0135
BT-20	Seliciclib	0.04	uM	LJP5	1	J06	72	hr	1657	5649	5624	1.0044	1.0050
BT-20	Seliciclib	0.04	uM	LJP5	2	J06	72	hr	1657	5742	5610	1.0234	1.0265
BT-20	Seliciclib	0.12	uM	LJP5	1	J05	72	hr	1657	5349	5624	0.9511	0.9439
BT-20	Seliciclib	0.12	uM	LJP5	2	J05	72	hr	1657	5765	5610	1.0275	1.0311
BT-20	Seliciclib	0.37	uM	LJP5	2	J04	72	hr	1657	5240	5610	0.9339	0.9238
BT-20	Seliciclib	0.37	uM	LJP5	3	J04	72	hr	1657	5100	5529	0.9223	0.9091
BT-20	Seliciclib	1.11	uM	LJP5	2	J03	72	hr	1657	4956	5610	0.8833	0.8638
BT-20	Seliciclib	1.11	uM	LJP5	3	J03	72	hr	1657	4738	5529	0.8569	0.8299
BT-20	Seliciclib	10	uM	LJP5	1	J01	72	hr	1657	2369	5624	0.4212	0.2245
BT-20	Seliciclib	10	uM	LJP5	2	J01	72	hr	1657	2227	5610	0.3969	0.1827
BT-20	AT-7519	0.04	uM	LJP6	1	K06	72	hr	1657	5160	5244	0.9838	0.9805
BT-20	AT-7519	0.04	uM	LJP6	2	K06	72	hr	1657	5258	5360	0.9809	0.9774
BT-20	AT-7519	0.12	uM	LJP6	2	K05	72	hr	1657	4398	5360	0.8205	0.7794
BT-20	AT-7519	0.12	uM	LJP6	3	K05	72	hr	1657	4202	5546	0.7577	0.7055
BT-20	AT-7519	0.37	uM	LJP6	2	K04	72	hr	1657	1973	5360	0.3681	0.1083
BT-20	AT-7519	0.37	uM	LJP6	3	K04	72	hr	1657	1881	5546	0.3392	0.0752
BT-20	AT-7519	3.33	uM	LJP6	2	K02	72	hr	1657	1094	5360	0.2041	-0.2177
BT-20	AT-7519	3.33	uM	LJP6	3	K02	72	hr	1657	1297	5546	0.2339	-0.1314
BT-20	AT-7519	10	uM	LJP6	2	K01	72	hr	1657	726	5360	0.1354	-0.3859
BT-20	Dasatinib	1.11	uM	LJP5	2	D03	72	hr	1657	1687	5610	0.3007	0.0100
BT-20	Dasatinib	1.11	uM	LJP5	1	D03	72	hr	1657	1528	5624	0.2717	-0.0452

|<
<<
Previous
Page 11 of 535
Next
>>
>
251 to 275 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)